Diabetic retinopathy progresses through four main stages, starting with tiny bulges in the blood vessels of the retina and potentially advancing to abnormal new blood vessel growth that threatens vision. The first three stages are grouped as nonproliferative diabetic retinopathy (NPDR), while the fourth and most advanced stage is proliferative diabetic retinopathy (PDR). Understanding where you fall on this spectrum matters because the earlier stages often cause no symptoms at all, and the risk of vision loss climbs sharply with each progression.
How Diabetes Damages the Retina
The retina is a thin layer of tissue lining the back of your eye that converts light into signals your brain reads as images. It depends on a dense network of tiny blood vessels to stay nourished. Chronically high blood sugar damages the cells that wrap around and support these capillaries, called pericytes. When pericytes die off, the capillary walls weaken. The membrane surrounding those vessels also thickens, reducing communication between the cells that keep vessels healthy. This sets the stage for every change that follows.
Stage 1: Mild NPDR
The earliest detectable sign of diabetic retinopathy is the appearance of microaneurysms, small balloon-like bulges in the weakened walls of retinal capillaries. At this stage, only a few microaneurysms are present, and they’re found during a dilated eye exam rather than from anything you’d notice in your vision. Most people feel completely normal. The retina is still functioning well, and blood flow disruption is minimal.
Even though this stage sounds minor, it signals that diabetes has begun affecting the eye. It’s the point where closer monitoring becomes important, because progression to the next stage isn’t inevitable if blood sugar, blood pressure, and cholesterol are well managed.
Stage 2: Moderate NPDR
As damage continues, the number of microaneurysms increases and small areas of bleeding appear in the retina (dot-and-blot hemorrhages). You may also develop cotton-wool spots, which are pale patches caused by interrupted blood flow to small sections of the retinal nerve layer, and hard exudates, yellowish deposits of leaked fats and proteins. Blood vessels are swelling and losing their ability to transport blood normally, which means parts of the retina are starting to be undernourished.
Vision is still often unaffected at this point, which is precisely what makes diabetic retinopathy dangerous. The disease can be progressing silently while you feel fine.
Stage 3: Severe NPDR
Severe NPDR means a significant portion of the retina’s blood vessels are now blocked or damaged. Eye specialists identify this stage using what’s called the 4-2-1 rule: widespread bleeding and microaneurysms across all four quadrants of the retina, or abnormal beading of the vein walls in two or more quadrants, or abnormal tangles of small blood vessels in one or more quadrants. Meeting any one of these criteria is enough.
At this point, large areas of the retina are being starved of oxygen. The eye is essentially sending distress signals, releasing chemical growth factors that urge the body to build new blood vessels to compensate. This is the critical transition zone. Without intervention, roughly half of people with severe NPDR will progress to the proliferative stage within a year. Some people begin to notice blurred vision here, though many still have no symptoms.
Stage 4: Proliferative Diabetic Retinopathy
PDR is the most advanced stage. In response to oxygen starvation, the retina triggers the growth of new blood vessels, a process called neovascularization. These vessels can sprout on the surface of the retina, on the optic disc, or even on the iris. The problem is that these new vessels are fragile and structurally abnormal. They leak easily and bleed into the vitreous, the clear gel filling the center of the eye.
A small bleed might show up as a sudden scattering of floaters or dark spots in your vision. A larger one can fill the vitreous cavity and block vision entirely. Over time, scar tissue forms along these new vessels. As that scar tissue contracts, it can pull the retina away from the back of the eye, causing a tractional retinal detachment. If abnormal vessels block the eye’s drainage system, fluid pressure builds and damages the optic nerve, leading to a form of glaucoma.
PDR progresses through its own internal phases. Fine new vessels first extend beyond the retina’s inner surface with minimal scar tissue. They then grow larger with an increasing fibrous component. Eventually the vessels themselves regress, but they leave behind a scaffold of fibrovascular tissue that continues to pose a threat of traction and detachment.
Diabetic Macular Edema
Diabetic macular edema (DME) deserves its own mention because it can develop at any stage of retinopathy, not just the advanced ones. It happens when damaged blood vessels leak fluid into the macula, the central part of the retina responsible for sharp, detailed vision. The macula swells, and you may notice blurred or wavy central vision, difficulty reading, or colors appearing washed out. DME is actually the most common reason people with diabetic retinopathy lose vision, and it can occur even in mild NPDR.
What Each Stage Feels Like
One of the most important things to understand is that the early and middle stages typically produce no symptoms whatsoever. You can have moderate or even severe NPDR without any change in how you see the world. This is why annual dilated eye exams are the primary way diabetic retinopathy gets caught.
Symptoms tend to appear once the disease reaches the proliferative stage or when macular edema develops. The most common complaints are floaters (dark spots or strings drifting across your vision), blurred vision, dark or empty areas in your visual field, and difficulty with color perception. Vision loss from a vitreous hemorrhage can come on suddenly. If scar tissue causes a retinal detachment, you may notice a shadow or curtain effect creeping across your vision.
How It’s Diagnosed and Monitored
A dilated eye exam remains the foundation of diagnosis. Your eye doctor uses drops to widen the pupil and then examines the retina directly, looking for microaneurysms, hemorrhages, vessel changes, and new blood vessel growth.
For more detailed imaging, two main technologies are used. Fluorescein angiography involves injecting a dye into a vein in your arm and photographing the retina as the dye travels through its blood vessels. It provides a wide view and can reveal leaking vessels and areas of poor blood flow, but it’s invasive and the dye occasionally causes side effects ranging from nausea to allergic reactions. Optical coherence tomography angiography (OCT-A) is a newer, noninvasive alternative that captures detailed images of retinal blood vessels without any dye injection. It can detect changes in vessel shape, measure the size of the central avascular zone (a key area near the macula), and identify blood flow abnormalities even before clinical symptoms appear. Its main limitations are a narrower field of view and an inability to show vascular leakage directly.
Treatment Across Stages
In the mild and moderate NPDR stages, treatment focuses on managing the underlying diabetes. Tighter blood sugar control, blood pressure management, and cholesterol reduction can slow progression and, in some cases, allow mild changes to improve on their own. Your eye doctor will typically monitor you with regular exams, adjusting the frequency based on how stable your findings are.
Severe NPDR and PDR require more direct intervention. The two primary approaches are laser treatment (panretinal photocoagulation, or PRP) and injections that block the growth signal driving abnormal blood vessel formation. PRP uses laser burns across the peripheral retina to reduce the oxygen demand that triggers new vessel growth. It’s been the standard treatment for decades and remains the recommended first-line therapy for high-risk PDR by both the American Academy of Ophthalmology and the Royal College of Ophthalmologists.
Injection therapy has gained ground, particularly when macular edema is also present. A 2024 analysis found that injections produced slightly better visual acuity results than laser at 3 and 12 months, though by 24 months outcomes were similar between the two. The practical difference in vision was small enough that it didn’t cross the threshold considered clinically meaningful. Injections did, however, result in fewer patients needing surgical removal of blood from the eye, and they were less likely to trigger new or worsening macular edema, a known side effect of laser treatment. Many retina specialists now use a combination of both approaches, tailoring the plan to the patient’s specific situation and ability to attend frequent follow-up visits.
For complications like vitreous hemorrhage that doesn’t clear on its own or tractional retinal detachment, surgical intervention to remove the vitreous gel and repair the retina becomes necessary. Serious complications such as glaucoma from abnormal vessel growth on the iris remain rare with either treatment approach, but they underscore why catching the disease before it reaches the proliferative stage makes such a difference.